北京纬晓生物技术开发

Beijing Weixiao Biological Technology Development (Weixiao Bio) is a biotechnology company headquartered in Beijing, China, dedicated to the advancement of circular RNA (circRNA) therapeutics. Founded in 2021, the company focuses on leveraging the unique structural stability of circRNA to develop long-acting vaccines and protein replacement therapies. Weixiao Bio utilizes a proprietary platform for circRNA design, synthesis, and lipid nanoparticle (LNP) encapsulation to optimize delivery and translation efficiency. Its research pipeline targets a broad range of applications, including infectious diseases, oncology, and metabolic disorders. The company has secured significant backing from prominent venture capital firms to accelerate its transition from platform development to clinical-stage programs.